

# [From the President's Desk](#)

written by CAP TODAY  
December 8, 2022

December 2022—Many of us were raised on alluring stories of the good old days in medicine, when physicians enjoyed long-term, respectful relationships with their patients. I grew up hearing from my father, an obstetrician/gynecologist, and my mother, a nurse, about their frustrating transition from this to a modern reality in which these relationships were strained by a seemingly impenetrable health care bureaucracy. Like so many pathologists, I have felt intimidated by such behemoths as the CMS, the FDA, and insurance companies, as well as smaller monoliths like the C-suites or dean's office at health systems and medical schools where I have practiced. But what I have realized by working with the CAP is that dealing with these entities can be more manageable when we create positive and productive relationships with the people who work in them.



©2026 CAP TODAY, all rights reserved.

---

# [FDA clears Roche Alzheimer's disease CSF assays](#)

written by CAP TODAY  
December 8, 2022

Dec. 8, 2022—Roche announced FDA 510(k) clearance of its Elecsys beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys Phospho-Tau (181P) CSF (pTau181) assays.



©2026 CAP TODAY, all rights reserved.

---

## [Clinical pathology selected abstracts](#)

written by CAP TODAY  
December 8, 2022

December 2022—Tranexamic acid is an antifibrinolytic drug that improves survival in adults with traumatic hemorrhage. To the authors' knowledge, it has not been evaluated in a trial of injured children.



©2026 CAP TODAY, all rights reserved.

---

## [Anatomic pathology selected abstracts](#)

written by CAP TODAY  
December 8, 2022

December 2022—Prostatic duct adenocarcinoma, which is characterized by pseudostratified columnar epithelium, has historically been considered invasive carcinoma, although it may have an intraductal component.



©2026 CAP TODAY, all rights reserved.

---

# Molecular pathology selected abstracts

written by CAP TODAY  
December 8, 2022

December 2022—Infantile-onset epilepsy has a variety of underlying etiologies, including brain injury, metabolic disorders, and genetic factors. Refractory epileptic conditions in infants can result in developmental delays, poor quality of life, and increased mortality rates.



©2026 CAP TODAY, all rights reserved.

---

## Q&A column

written by CAP TODAY  
December 8, 2022

### **December 2022**

**Q.** What is the appropriate way to measure or identify microcytosis or macrocytosis? [Read answer.](#)

**Q.** A six-year-old female with B-cell acute lymphoblastic leukemia and Rh-negative blood is being treated with myeloablative chemotherapy to achieve durable remission or as a bridge to stem cell transplantation, during which supportive transfusions will include repeated platelet transfusions over many weeks. Clinicians are concerned that the patient could become alloimmunized to the D antigen, which, in turn, could affect her ability to eventually bear children.

Apheresis platelets contain a small but finite amount of RBC contaminants, which are not usually quantitated. An optimal strategy to prevent anti-D alloimmunization is to use Rh-negative platelets, but they are often in short supply and cannot be ordered stat in a timely enough manner to ensure every platelet transfusion episode is Rh-negative. We considered using Rh immune globulin (RhIg). However, we recognize that commercial RhIg is designed to prevent D alloimmunization in the setting of obstetric fetal-maternal bleeding.

Is there an optimal dose for RhIg or suggested timing of administration to prevent anti-D alloimmunization in this setting? [Read answer.](#)



©2026 CAP TODAY, all rights reserved.

---

## Newsbytes

written by CAP TODAY  
December 8, 2022

December 2022—To safely and effectively extend the process of conducting point-of-care testing to staff from various hospital departments is no easy feat. That’s why four full-time employees at Children’s Hospital Los Angeles oversee POC testing, relying heavily on middleware, analytics, and exception-management tools.



©2026 CAP TODAY, all rights reserved.

---

## Put It on the Board

written by CAP TODAY  
December 8, 2022

December 2022—The Food and Drug Administration has approved the Ventana FOLR1 (FOLR1-2.1) RxDx Assay, the first immunohistochemistry companion diagnostic test to aid in identifying epithelial ovarian cancer patients who are eligible for targeted treatment with Elahere (mirvetuximab soravtansine-gynx). Elahere is a first-in-class antibody-drug conjugate therapy developed by Immuno-Gen and approved under the FDA’s accelerated approval program for the treatment of FR $\alpha$ -positive platinum-resistant ovarian cancer.

## [FDA clears HemoSonics Quantra with QStat cartridge](#)

written by CAP TODAY  
December 8, 2022

Dec. 1, 2022—HemoSonics received FDA 510(k) clearance for the Quantra hemostasis system with QStat cartridge.

## [General Data launches LaserTrack Flex for histology labs](#)

written by CAP TODAY  
December 8, 2022

Nov. 29, 2022—General Data Healthcare launched its LaserTrack Flex cassette printer.

